Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Express Scripts Excludes Valeant, Eli Lilly Drugs from New Formulary List

By Ryan Bushey | August 3, 2016

Express Scripts posted its new formulary list on Monday, which is a run-down of the drugs it plans to cover under its insurance plan for the following year.

The pharmacy benefits manager decided to exclude 85 drugs from this list for 2017. That figure is slightly smaller than the 87 that were left off it in 2016.

Some of the notable omissions from this list include Valeant Pharmaceutical’s actinic keratosis cream Zyclara, Bristol-Myers Squibb’s arthritis treatment Orencia, as well as Eli Lilly’s psoriasis therapy Taltz, reported Reuters. A spokesperson for Express Scripts, David Whitrap, told the publication the expensive hepatitis C drugs Epclusa and Harvoni will remain on the excluded list, but their status could change by the end of the year.

Also, two arthritis drugs made by Pfizer along with another set of asthma treatments developed by GlaxoSmithKline will be added to Express Script’s list for 2017. They will be considered “preferred alternatives” after price negotiations were conducted between the pharmacy benefits manager and the companies, according to Reuters.

The idea behind removing certain drugs from this list could give Express Scripts more bargaining power when it comes to drug pricing and save money for individual insurers and corporate customers. This program may help participants save an estimated $1.8 billion next year, according to Express Scripts.


Filed Under: Drug Discovery

 

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50